|
1
|
Croatian National Cancer Registry: Cancer
incidence in Croatia 2015. Bulletin No. 40. Zagreb, Croatian
National Institute of Public Health. 2018.
|
|
2
|
Balmaňa J, Balanguer F, Cervantes A and
Arnold D: Familial risk-colorectal cancer: ESMO clinical practice
guidelines. Ann Oncol. 24 (Suppl 6):vi73–vi80. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tikhmyanova N and Golemis EA: NEDD9 and
BCAR1 negatively regulate E-cadherin membrane localization, and
promote E-cadherin degradation. PLoS One. 6:e221022011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huntsman DG and Caldas C: Assignment of
the E-cadherin gene (CDH1) to chromosome 16q22.1 by radiation
hybrid mapping. Cytogenet Cell Genet. 83:82–83. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fleming TP, Javed Q and Hay M: Epithelial
differentiation and intercellular junction formation in the mouse
early embryo. Dev Suppl. 105–112. 1992.PubMed/NCBI
|
|
6
|
Paschos KA, Canovas D and Bird NC: The
role of cell adhesion molecules in the progression of colorectal
cancer and the development of liver metastasis. Cell Signal.
21:665–674. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
El-Bahrawy MA, Poulsom R, Jeffery R,
Talbot I and Alison MR: The expression of E-cadherin and catenins
in sporadic colorectal carcinoma. Hum Pathol. 32:1216–1224. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pećina-Slaus N: Tumor suppressor gene
E-cadherin and its role in normal and malignant cells. Cancer Cell
Int. 3:172003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tikhmyanova N, Little JL and Golemis EA:
CAS proteins in normal and pathological cell growth control. Cell
Mol Life Sci. 67:1025–1048. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kong C, Wang C, Wang L, Ma M, Niu C, Sun
X, Du J, Dong Z, Zhu S, Lu J and Huang B: NEDD9 is a positive
regulator of epithelial-mesenchymal transition and promotes
invasion in aggressive breast cancer. PLoS One. 6:e226662011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Štajduhar E, Sedić M, Leniček T, Radulović
P, Kerenji A, Krušlin B, Pavelić K and Kraljević Pavelić A:
Expression of growth hormone receptor, plakoglobin and NEDD9
protein in association with tumour progression and metastasis in
human breast cancer. Tumor Biol. 35:6425–6434. 2014. View Article : Google Scholar
|
|
12
|
Zhang SS, Wu LH, Liu Q, Chen KS and Zhang
XF: Elevated expression of NEDD9 is associated with metastatic
activity in gastric cancer. Onco Targets Ther. 8:633–640. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chang JX, Gao F, Zhao GQ and Zhang GJ:
Expression and clinical significance of NEDD9 in lung tissue. Med
Oncol. 29:2654–2660. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim M, Gans JD, Nogueira C, Wang A, Paik
JH, Feng B, Brennan C, Hahn WC, Cordon-Cardo C, Wagner SN, et al:
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis
gene. Cell. 125:1269–1281. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang H, Mu X, Zhou S, Zhang J, Dai J, Tang
L, Xiao L, Duan Z, Jia L and Chen S: NEDD9 overexpression is
associated with the progression of and an unfavorable prognosis in
epithelial ovarian cancer. Hum Pathol. 45:401–408. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang Z, Shen M, Lu P, Li X, Zhu S and Yue
S: NEDD9 may regulate hepatocellular carcinoma cell metastasis by
promoting epithelial-mesenchymal-transition and stemness via
repressing Smad7. Oncotarget. 8:1714–1724. 2017.PubMed/NCBI
|
|
17
|
Xue YZ, Sheng YY, Liu ZL, Wei ZQ, Cao HY,
Wu YM, Lu YF, Yu LH, Li JP and Li ZS: Expression of NEDD9 in
pancreatic ductal adenocarcinoma and its clinical significance.
Tumour Biol. 34:895–899. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Morimoto K, Tanaka T, Nitta Y, Ohnishi K,
Kawashima H and Nakatani T: NEDD9 crucially regulates
TGF-β-triggered epithelial-mesenchymal transition and cell invasion
in prostate cancer cells: Involvement in cancer progressiveness.
Prostate. 74:901–910. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang J, Wang S, Luan Y, Zhang W, Sun C,
Cheng G, Li K, Xin Q, Lin Z, Qi T and Kong F: Overexpression of
NEDD9 in renal cell carcinoma is associated with tumor migration
and invasion. Oncol Lett. 14:8021–8027. 2017.PubMed/NCBI
|
|
20
|
Cui X, Shen K, Xie Z, Liu T and Zhang H:
Identification of key genes in colorectal cancer using random walk
with restart. Mol Med Rep. 15:867–872. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hong SM, Li A, Olino K, Wolfgang CL,
Herman JM, Schulick RD, Iacobuzio-Donahue C, Hruban RH and Goggins
M: Loss of E-cadherin expression and outcome among patients with
resectable pancreatic adenocarcinomas. Mod Pathol. 24:1237–1247.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yun JA, Kim SH, Hong HK, Yun SH, Kim HC,
Chun HK, Cho YB and Lee WY: Loss of E-Cadherin expression is
associated with a poor prognosis in stage III colorectal cancer.
Oncology. 86:318–328. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dorudi S, Sheffield JP, Poulsom R,
Northover JM and Hart IR: E-cadherin expression in colorectal
cancer. An immunocytochemical and in situ hybridization study. Am J
Pathol. 142:981–986. 1993.PubMed/NCBI
|
|
24
|
Miladi-Abdennadher I, Abdelmaksoud-Dammak
R, Ayed-Guerfali DB, Ayadi L, Khabir A, Amouri A, Frikha F, Tahri
N, Ellouz S, Frikha M, et al: Expression of COX-2 and E-cadherin in
Tunisian patients with colorectal adenocarcinoma. Acta Histochem.
114:577–581. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Palaghia M, Mihai C, Lozneanu L, Ciobanu
D, Trofin AM, Rotariu A, Târcoveanu F and Cijevschi Prelipcean C:
E-cadherin expression in primary colorectal cancer and metastatic
lymph nodes. Rom J Morphol Embryol. 57:205–209. 2016.PubMed/NCBI
|
|
26
|
Elzagheid A, Buhmeida A, Laato M,
El-Faitori O, Syrjänen K, Collan Y and Pyrhönen S: Loss of
E-cadherin expression predicts disease recurrence and shorter
survival in colorectal carcinoma. APMIS. 120:539–548. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gu J, Zhu X, Ye Y, Qu J, Huang L, Li R, Yu
Y and Leng X: The level of expression of adhesion molecules CD44v6
and E-cadherin in colorectal cancer and analysis of correlates with
metastasis. Zhonghua Wai Ke Za Zhi. 37:108–109. 4–1999.(In
Chinese). PubMed/NCBI
|
|
28
|
Elzagheid A, Algars A, Bendardaf R, Lamlum
H, Ristamaki R, Collan Y, Syrjanen K and Pyrhonen S: E-cadherin
expression pattern in primary colorectal carcinomas and their
metastases reflects disease outcome. World J Gastroenterol.
12:4304–4309. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tóth L, András C, Molnár C, Tanyi M, Csiki
Z, Molnár P and Szántó J: Investigation of β-catenin and E-cadherin
expression in Dukes B2 stage colorectal cancer with tissue
microarray method. Is it a marker of metastatic potential in rectal
cancer? Pathol Oncol Res. 18:429–437. 2012.PubMed/NCBI
|
|
30
|
Khoursheed MA, Mathew TC, Makar RR, Louis
S, Asfar SK, Al-Sayer HM, Dashti HM and Al-Bader A: Expression of
E-cadherin in human colorectal cancer. Surgeon. 1:86–91. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Roca F, Mauro LV, Morandi A, Bonadeo F,
Vaccaro C, Quintana GO, Specterman S, de Kier Joffé EB, Pallotta
MG, Puricelli LI and Lastiri J: Prognostic value of E-cadherin,
beta-catenin, MMPs (7 and 9), and TIMPs (1 and 2) in patients with
colorectal carcinoma. J Surg Oncol. 93:151–160. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ghadimi BM, Behrens J, Hoffmann I, Haensch
W, Birchmeier W and Schlag PM: Immunohistological analysis of
E-cadherin, alpha-, beta- and gamma-catenin expression in
colorectal cancer: Implications for cell adhesion and signaling.
Eur J Cancer. 35:60–65. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kwak JM, Min BW, Lee JH, Choi JS, Lee SI,
Park SS, Kim J, Um JW, Kim SH and Moon HY: The prognostic
significance of E-cadherin and liver intestine-cadherin expression
in colorectal cancer. Dis Colon Rectum. 50:1873–1880. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lugli A, Zlobec I, Minoo P, Baker K,
Tornillo L, Terracciano L and Jass JR: Prognostic significance of
the wnt signalling pathway molecules APC, beta-catenin and
E-cadherin in colorectal cancer: A tissue microarray-based
analysis. Histopathology. 50:453–464. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Karamitopoulou E, Zlobec I, Patsouris E,
Peros G and Lugli A: Loss of E-cadherin independently predicts the
lymph node status in colorectal cancer. Pathology. 43:133–137.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ozgüven BY, Karaçetin D, Kabukçuoğlu F,
Taşkin T and Yener Ş: Immunohistochemical study of E-cadherin and
β-catenin expression in colorectal carcinomas. Pol J Pathol.
62:19–24. 2011.PubMed/NCBI
|
|
37
|
Kim SA, Inamura K, Yamauchi M, Nishihara
R, Mima K, Sukawa Y, Li T, Yasunari M, Morikawa T, Fitzgerald KC,
et al: Loss of CDH1 (E-cadherin) expression is associated with
infiltrative tumour growth and lymph node metastasis. Br J Cancer.
114:199–206. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ikeguchi M, Taniguchi T, Makino M and
Kaibara N: Reduced E-cadherin expression and enlargement of cancer
nuclei strongly correlate with hematogenic metastasis in colorectal
adenocarcinoma. Scand J Gastroenterol. 35:839–846. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kim JC, Roh SA, Kim HC, Koo KH, Cho YK, Yu
CS, Kwon YM and Kim JS: Coexpression of carcinoembryonic antigen
and E-cadherin in colorectal adenocarcinoma with liver metastasis.
J Gastrointest Surg. 7:931–938. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mohri Y: Prognostic significance of
E-cadherin expression in human colorectal cancer tissue. Surg
Today. 27:606–612. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nanashima A, Yamaguchi H, Sawai T,
Yamaguchi E, Kidogawa H, Matsuo S, Yasutake T, Tsuji T, Jibiki M,
Nakagoe T and Ayabe H: Prognostic factors in hepatic metastases of
colorectal carcinoma: Immunohistochemical analysis of tumor
biological factors. Dig Dis Sci. 46:1623–1628. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kaihara T, Kusaka T, Nishi M, Kawamata H,
Imura J, Kitajima K, Itoh-Minami R, Aoyama N, Kasuga M, Oda Y, et
al: Dedifferentiation and decreased expression of adhesion
molecules, E-cadherin and ZO-1, in colorectal cancer are closely
related to liver metastasis. J Exp Clin Cancer Res. 22:117–123.
2003.PubMed/NCBI
|
|
43
|
Truant SC, Gouyer VP, Leteurtre EA,
Zerimech F, Huet GM and Pruvot FR: E-cadherin and beta-catenin mRNA
levels throughout colon cancer progression. J Surg Res.
150:212–218. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gagliardi G, Kandemir O, Liu D, Guida M,
Benvestito S, Ruers TG, Benjamin IS, Northover JM, Stamp GW, Talbot
IC, et al: Changes in E-cadherin immunoreactivity in the
adenoma-carcinoma sequence of the large bowel. Virchows Arch.
426:149–154. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kang H, Min BS, Lee KY, Kim NK, Kim SN,
Choi J and Kim H: Loss of E-cadherin and MUC2 expressions
correlated with poor survival in patients with stages II and III
colorectal carcinoma. Ann Surg Oncol. 18:711–719. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lee SJ, Choi SY, Kim WJ, Ji M, Lee TG, Son
BR, Yoon SM, Sung R, Lee EJ, Youn SJ and Park SM: Combined aberrant
expression of E-cadherin and S100A4, but not β-catenin is
associated with disease-free survival and overall survival in
colorectal cancer patients. Diagn Pathol. 8:992013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Xia D, Holla VR, Wang D, Menter DG and
DuBois RN: HEF1 is a crucial mediator of the proliferative effects
of prostaglandin E(2) on colon cancer cells. Cancer Res.
70:824–831. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li P, Zhou H, Zhu X, Ma G, Liu C, Lin B
and Mao W: High expression of NEDD9 predicts adverse outcomes of
colorectal cancer patients. Int J Clin Exp Pathol. 7:2565–2570.
2014.PubMed/NCBI
|
|
49
|
Li Y, Bavarva JH, Wang Z, Guo J, Qian C,
Thibodeau SN, Golemis EA and Liu W: HEF1, a novel target of Wnt
signaling, promotes colonic cell migration and cancer progression.
Oncogene. 30:2633–2643. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Awasthi S, Maity T, Oyler BL, Qi Y, Zhang
X, Goodlett DR and Guha U: Quantitative targeted proteomic analysis
of potential markers of tyrosine kinase inhibitor (TKI) sensitivity
in EGFR mutated lung adenocarcinoma. J Proteomics. 189:48–59. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Miao Y, Li AL, Wang L, Fan CF, Zhang XP,
Xu HT, Yang LH, Liu Y and Wang EH: Overexpression of NEDD9 is
associated with altered expression of E-Cadherin, β-Catenin and
N-Cadherin and predictive of poor prognosis in non-small cell lung
cancer. Pathol Oncol Res. 19:281–286. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang R, Zhang X, Ma B, Xiao B, Huang F,
Huang P, Ying C, Liu T and Wang Y: Enhanced antitumor effect of
combining TRAIL and MnSOD mediated by CEA-controlled oncolytic
adenovirus in lung cancer. Cancer Gene Ther. 23:168–177. 2016.
View Article : Google Scholar : PubMed/NCBI
|
